| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
63,632,000 |
| Market
Cap: |
1.59(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$24.98 - $24.98 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Provention Bio is a biopharmaceutical company. Co.'s pipeline of investigational candidates under development includes: PRV-031 (teplizumab), an anti-CD3 monoclonal antibody (mAb) for the delay of clinical Type 1 Diabetes (T1D); PRV-3279, a bispecific scaffold molecule targeting the B-cell surface proteins, FcgammaRIIb and CD79B, for the treatment of systemic lupus erythematosus; PRV-015 (ordesekimab), an anti-interleukin 15 mAb for the treatment of gluten-free diet non-responsive celiac disease; and PRV-101, a Coxsackie Virus B (CVB) vaccine to prevent acute CVB infections and to prevent the CVB-triggered autoimmune damage to pancreatic beta cells that may progress to T1D.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
5,594,666 |
| Total Sell Value |
$0 |
$0 |
$0 |
$85,590,128 |
| Total People Sold |
0 |
0 |
0 |
4 |
| Total Sell Transactions |
0 |
0 |
0 |
13 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Digiandomenico Anthony |
Director |
– • – |
2018-12-24 |
4 |
B |
$1.92 |
$33,158 |
D/D |
17,270 |
53,712 |
2.39 |
- |
|
| Catlin Avery W |
Director |
– • – |
2018-12-24 |
4 |
B |
$1.90 |
$9,500 |
I/I |
5,000 |
15,000 |
2.1 |
- |
|
| Digiandomenico Anthony |
Director |
– • – |
2018-12-21 |
4 |
B |
$1.85 |
$3,700 |
D/D |
2,000 |
36,442 |
2.31 |
- |
|
| Digiandomenico Anthony |
Director |
– • – |
2018-12-20 |
4 |
B |
$1.96 |
$9,800 |
D/D |
5,000 |
34,442 |
2.39 |
- |
|
| Digiandomenico Anthony |
Director |
– • – |
2018-12-03 |
4 |
B |
$2.45 |
$10,883 |
D/D |
4,442 |
29,442 |
2.39 |
- |
|
| Digiandomenico Anthony |
Director |
– • – |
2018-11-30 |
4 |
B |
$2.45 |
$11,880 |
D/D |
4,849 |
25,000 |
2.39 |
- |
|
| Digiandomenico Anthony |
Director |
– • – |
2018-11-29 |
4 |
B |
$2.47 |
$373 |
D/D |
151 |
20,151 |
2.31 |
- |
|
| Digiandomenico Anthony |
Director |
– • – |
2018-11-27 |
4 |
B |
$2.46 |
$24,600 |
D/D |
10,000 |
20,000 |
2.39 |
- |
|
| Digiandomenico Anthony |
Director |
– • – |
2018-11-26 |
4 |
B |
$2.65 |
$26,500 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| Drechsler Andrew T |
Chief Financial Officer |
• – – |
2018-11-13 |
4 |
OE |
$2.50 |
$25,000 |
D/D |
10,000 |
16,250 |
|
- |
|
| Catlin Avery W |
Director |
– • – |
2018-11-09 |
4 |
B |
$3.15 |
$31,500 |
I/I |
10,000 |
10,000 |
2.1 |
- |
|
| Appel Peter A |
10% Owner |
– – • |
2018-07-19 |
4 |
B |
$4.00 |
$3,000,000 |
D/D |
750,000 |
1,950,000 |
2.45 |
- |
|
| Appel Peter A |
10% Owner |
– – • |
2018-07-19 |
4 |
A |
$0.00 |
$0 |
D/D |
1,200,000 |
1,200,000 |
|
- |
|
| Johnson & Johnson Development Corp Et Al |
10% Owner |
– – • |
2018-07-19 |
4 |
A |
$0.00 |
$0 |
I/I |
2,400,000 |
2,400,000 |
|
- |
|
| Pisano Wayne |
Director |
– • – |
2018-07-19 |
4 |
B |
$4.00 |
$10,000 |
D/D |
2,500 |
2,500 |
2.39 |
- |
|
| Ramos Eleanor |
Chief Medical Officer & COO |
• – – |
2018-07-19 |
4 |
B |
$4.00 |
$240,000 |
D/D |
60,000 |
60,000 |
2.74 |
- |
|
| Drechsler Andrew T |
Chief Financial Officer |
• – – |
2018-07-19 |
4 |
B |
$4.00 |
$25,000 |
D/D |
6,250 |
6,250 |
2.74 |
- |
|
| Leon Francisco |
Chief Scientific Officer |
• • • |
2018-07-19 |
4 |
B |
$4.00 |
$150,000 |
D/D |
37,500 |
2,537,500 |
3.23 |
- |
|
| Palmer Ashleigh |
President and CEO |
• • • |
2018-07-19 |
4 |
B |
$4.00 |
$150,000 |
D/D |
37,500 |
2,537,500 |
3.23 |
- |
|
94 Records found
|
|
Page 4 of 4 |
|
|
